A study evaluating efficacy and safety of topiroxostat in Japanese patients with hyperuricemia (with or without gout).

Trial Profile

A study evaluating efficacy and safety of topiroxostat in Japanese patients with hyperuricemia (with or without gout).

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Apr 2017

At a glance

  • Drugs Topiroxostat (Primary) ; Allopurinol
  • Indications Hyperuricaemia
  • Focus Therapeutic Use
  • Sponsors Fuji Yakuhin
  • Most Recent Events

    • 01 Apr 2017 New trial record
    • 01 Mar 2017 Primary endpoint (serum urate reduction rate from baseline to final visit compared to placebo) has been met.
    • 01 Mar 2017 Results published in the Clinical Rheumatology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top